Latest Headlines

Latest Headlines

Curis snags $30M loan, grabs early-stage cancer drug from Genentech

And Curis immediately spent a big chunk of that to in-license an experimental cancer therapy from its colleagues at Genentech, flipping the usual order of deal-making as the little biotech paid the giant Roche subsidiary a small upfront to gain development rights.

UPDATED: Roche/Genentech drug beats back treatment-resistant breast cancer cells

A skin cancer drug developed by Roche/Genentech appears to beat back breast cancer cells resistant to tamoxifen, a standard course of treatment, researchers from Ohio have discovered.